Scott E Gygax

8247170, Aug 21, 2012

May 18, 2009

12/454408

Scott Elliott Gygax - Bordentown NJ, US
Aditya Prasad - Marlton NJ, US
Martin E. Adelson - Belle Mead NJ, US
Eli Mordechai - Robbinsville NJ, US

Medical Diagnostic Laboratories, LLC - Hamilton NJ

C12Q 1/68
C12P 19/34
C07H 21/04

435 61, 435 611, 435 612, 536 243, 536 2433

Disclosed are methods of detecting penicillin tolerance in Group B by detecting at least one of two single nucleotide polymorphisms (SNP) in penicillin binding protein 4. Also disclosed are primers and hybridization probes that may be used in such methods.

20090305274, Dec 10, 2009

Mar 12, 2009

12/381492

Scott E. Gygax - Bordentown NJ, US
John-Paul Vermitsky - Philadelphia PA, US
Sean G. Chadwick - Florence NJ, US
Matthew J. Self - Westmont NJ, US
Eli Mordechai - Robbinsville NJ, US
Martin E. Adelson - Belle Mead NJ, US

Medical Diagnostic Laboratories, LLC - Hamilton NJ

C12Q 1/68

435 6

There is disclosed a method for determining azole resistance in . A biological sample containing is obtained and a normalized mRNA level of CDR1 gene is determined using qRT-PCR. Using a microbroth dilution assay conducted at azole concentrations of about 2-8 μg/mL, a susceptible isolate of is obtained. A qRT-PCR assay is employed on the susceptible isolate and an average mRNA level of CDR1 is obtained. A fold-change value for CDR1 is obtained by comparing the CDR1 mRNA level of the biological sample with that of the average mRNA level. A ≧-fold change value is indicative of an azole resistance in . The present method provides a qRT-PCR assay for azole resistance that has a sensitivity of ≧90% and a specificity of ≧90%.

20110312876, Dec 22, 2011

Jan 13, 2011

12/930663

Scott Elliot Gygax - Yardley PA, US
Christina Lim Overmyer - Edison NJ, US
Lisa A. DeSalvia - Glenwood NJ, US
Martin E. Adelson - East Wiindsor NJ, US
Eli Mordechai - Robbinsville NJ, US

Medical Diagnostic Laboratories, LLC - Hamilton NJ

A61K 38/14
A61P 31/04
C12Q 1/68
A61K 31/5377
C40B 30/00
C07H 21/04

514 27, 506 7, 536 2433, 435 612, 5142368

Disclosed are diagnostic methods for determining a subtype of methicillin-resistant (MRSA) in a biological sample of a mammal. Methods include providing a biological sample of the mammal, performing a PCR analysis of the biological sample, and analyzing the PCR amplicons with respect to their sizes so as to determine for type I, type II, type III, type IV or type V MRSA that may be present in the biological sample. Further example embodiments include using at least one mecA primer pair and/or using at least one nuc primer pair in the PCR analysis. Further disclosed are methods for screening populations for MRSA, and methods of treating a mammal testing positive for Type IV MRSA. Also disclosed are kits for determining a MRSA subtype in a mammal and isolated primers that may be used in the present methods and kits.

20120009572, Jan 12, 2012

May 9, 2011

13/068331

Scott E. Gygax - Yardley PA, US
Sean Chadwick - Florence NJ, US
Aditya Prasad - Marlton NJ, US
Martin E. Adelson - East Windsor NJ, US
Eli Mordechai - Robbinsville NJ, US

Medical Diagnostic Laboratories, LLC - Hamilton NJ

C12Q 1/68

435 611

The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in . The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.

20120071336, Mar 22, 2012

Jun 2, 2011

13/134252

Sergey Balashov - Hamilton NJ, US
Eli Mordechai - Robbinsville NJ, US
Martin E. Adelson - East Windsor NJ, US
Scott E. Gygax - Yardley PA, US

Medical Diagnostic Laboratories, LLC - Hamilton NJ

C40B 30/04
C12Q 1/68

506 9, 435 612, 435 611

The present invention relates to an antibiotic resistance profile for by assessing the presence of mutations (e.g., SNP) in antibiotic resistant genes that confer bacterial resistance against antibiotics such as penicillin, tetracycline, fluoroquinolones, cephalosporin, macrolides and spectinomycin. There is provided a method and a kit for generating an antibiotic resistance profile for by utilizing a multiplex PCR to amplify segments of antibiotic-resistant genes, allele-specific primer extension to detect gene mutation, and detection of such gene mutations with gel electrophoresis, capillary electrophoresis, or DNA microarray. The present method provides useful information to physicians relating the antibiotic susceptibility of against different classes of antibiotics. Relying on this personalized diagnostic tool, physicians can better inform about antibiotic susceptibility and thereby open up medical intervention avenues for treating with antibiotics. There is provided a therapeutic application of the antibiotic resistance profile that has advantages of: (i) providing a more effective regime for gonorrhea treatment; and (ii) halting the evolutionary pressures towards antibiotic resistance in the therapy.

20170314065, Nov 2, 2017

Jul 14, 2017

15/649969

Scott E. Gygax - Yardley PA, US
Sean Chadwick - Florence NJ, US
Aditya Prasad - Marlton NJ, US
Martin E. Adelson - East Windsor NJ, US
Eli Mordechai - Robbinsville NJ, US

Medical Diagnostic Laboratories, LLC - Hamilton NJ

C12Q 1/68

The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in . The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.

20170260570, Sep 14, 2017

Mar 11, 2016

15/067700

Sergey Balashov - Hamilton NJ, US
Eli Mordechai - Robbinsville NJ, US
Martin E. Adelson - East Windsor NJ, US
Scott E. Gygax - Yardley PA, US

C12Q 1/68

The present invention relates to an antibiotic resistance profile for by assessing the presence of mutations (e.g., SNP) in antibiotic resistant genes that confer bacterial resistance against antibiotics such as penicillin, tetracycline, fluoroquinolones, cephalosporin, macrolides and spectinomycin. There is provided a method and a kit for generating an antibiotic resistance profile for by utilizing a multiplex PCR to amplify segments of antibiotic-resistant genes, allele-specific primer extension to detect gene mutation, and detection of such gene mutations with gel electrophoresis, capillary electrophoresis, or DNA microarray. The present method provides useful information to physicians relating the antibiotic susceptibility of against different classes of antibiotics. Relying on this personalized diagnostic tool, physicians can better inform about antibiotic susceptibility and thereby open up medical intervention avenues for treating with antibiotics. There is provided a therapeutic application of the antibiotic resistance profile that has advantages of: (i) providing a more effective regime for gonorrhea treatment; and (ii) halting the evolutionary pressures towards antibiotic resistance in the therapy.